Current Evidence for Cardiac Myosin Inhibitors: Where Are We in 2025?
Presenter:
We Recommend
Disclosures
Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:
- Consultant Fee/Honoraria/Speaker's Bureau - cytokinetics; edgewise; Imbria
Video Player is loading.